There are 2934 resources available
Poster Discussion – Sarcoma - Invited Discussant 1678PD and 1679PD
Presenter: Hans-Ulrich Schildhaus
Session: Poster Discussion – Sarcoma
Resources:
Slides
Webcast
Poster Discussion – Supportive and palliative care - Invited Discussant 1755PD, 1756PD and 1757PD
Presenter: Paolo Bossi
Session: Poster Discussion – Supportive and palliative care
Resources:
Slides
Webcast
4132 - Prospective, multicenter registry trial to evaluate the clinical feasibility of targeted axillary dissection (TAD) in patients (pts) with breast cancer (BC) and core biopsy proven axillary involvement (cN+)
Presenter: Mattea Reinisch
Session: Poster Discussion - Breast cancer, early stage
Resources:
Abstract
5429 - Long-term results of the PACS 04 trial evaluating adjuvant Epirubicin plus Docetaxel in node-positive breast cancer and Trastuzumab in the HER2-positive subgroup
Presenter: Veronique D'Hondt
Session: Poster Discussion - Breast cancer, early stage
Resources:
Abstract
3790 - Tumor size and overall survival in a cohort of young (_40 years), node negative, systemically untreated breast cancer patients; by the PARADIGM study group.
Presenter: Vincent De Jong
Session: Poster Discussion - Breast cancer, early stage
Resources:
Abstract
4332 - Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC)
Presenter: Jenny Furlanetto
Session: Poster Discussion - Breast cancer, early stage
Resources:
Abstract
1375 - Improved survival of older patients with advanced breast cancer due to an increase in systemic treatments – a population-based study
Presenter: Nienke De Glas
Session: Poster Discussion - Breast cancer, early stage
Resources:
Abstract
5704 - Safety and Efficacy of TRIplet combination of Nivolumab (N) with Dabrafenib (D) and Trametinib (T) [TRIDeNT] in Patients (pts) with BRAF-mutated Metastatic Melanoma (MM): A Single Center Phase II Study
Presenter: Elizabeth Burton
Session: Poster Discussion – Melanoma and other skin tumours
Resources:
Abstract
4298 - 3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial)
Presenter: Christian Blank
Session: Poster Discussion – Melanoma and other skin tumours
Resources:
Abstract
4560 - Cell Phenotypes Associated with Response and Toxicity Defined by High Resolution Flow Cytometry in Melanoma Patients receiving Checkpoint Inhibition
Presenter: Jeffrey Weber
Session: Poster Discussion – Melanoma and other skin tumours
Resources:
Abstract